The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | CAR-T for myeloma: the show must go on
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the use of CAR T-cell therapy in R/R multiple myeloma. Specifically, Prof. Mohty touches on advances in cellular therapies, the very encouraging results being seen from current research and the movement of CAR-T into the frontline. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
